Italian doctors track new lung cancer drug combo in real patients
NCT ID NCT07190677
Summary
This study is collecting real-world information on how well a new combination of immunotherapy drugs (nivolumab and ipilimumab) plus a short course of chemotherapy works for people with advanced non-small cell lung cancer that has spread. It will follow 300 patients across Italy to see how long they live, how long the cancer stays controlled, and what side effects occur. The goal is to understand how this approved treatment performs in everyday medical practice outside of a controlled clinical trial.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fondazione IRCCS Policlinico San Matteo
RECRUITINGPavia, Lombardy, 27100, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.